Oncolytic herpes simplex virus engineering and preparation

Methods in Molecular Biology

Volumn 797, Issue , 2012, Pages 1-19

  Agarwalla, Pankaj K ^a   Aghi, Manish K ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

G47 ; HSV BAC; Oncolytic virus; Virus purification; Virus titer

Indexed keywords

ANTIVIRUS AGENT; GANCICLOVIR; ONCOLYTIC VIRUS;

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; DRUG EFFECT; GENE VECTOR; GENETIC ENGINEERING; GENETIC RECOMBINATION; GENETICS; HERPES SIMPLEX VIRUS 1; HUMAN; ISOLATION AND PURIFICATION; METHODOLOGY; ONCOLYTIC VIROTHERAPY; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CHROMOSOMES, ARTIFICIAL, BACTERIAL; GANCICLOVIR; GENETIC ENGINEERING; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; HUMANS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; RECOMBINATION, GENETIC; VIRUS REPLICATION;

BACTERIA (MICROORGANISMS); DNA VIRUSES; HUMAN HERPESVIRUS 1; SIMPLEXVIRUS;

EID: 80555144267     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-340-0_1     Document Type: Chapter

References (12)

1. Chiocca, E. A. (2002). Oncolytic viruses. Nat Rev Cancer 2, 938–50.
2. Aghi, M., and Chiocca, E. A. (2003). Genetically engineered herpes simplex viral vectors in the treatment of brain tumors: a review. Cancer Invest 21, 278–92.
3. Shen, Y., and Nemunaitis, J. (2006). Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther 13, 975–92.
4. Aghi, M., and Martuza, R. (2005). Oncolytic viral therapies-the clinical experience. Oncogene 24, 7802–16.
5. Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., and Coen, D. M. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854–6.
6. Markert, J. M., Parker, J. N., Buchsbaum, D. J., Grizzle, W. E., Gillespie, G. Y., and Whitley, R. J. (2006). Oncolytic HSV-1 for the treatment of brain tumours. Herpes: the journal of the IHMF 13, 66–71.
7. Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D., and Martuza, R. L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1, 938–43.
8. Kramm, C. M., Chase, M., Herrlinger, U., Jacobs, A., Pechan, P. A., Rainov, N. G., Sena-Esteves, M., Aghi, M., Barnett, F. H., Chiocca, E. A., and Breakefield, X. O. (1997). Therapeutic efficiency and safety of a second-generation rep-lication-conditional HSV1 vector for brain tumor gene therapy. Hum Gene Ther 8, 2057–68.
9. Ino, Y., Saeki, Y., Fukuhara, H., and Todo, T. (2006). Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 12, 643–52.
10. Fukuhara, H., Ino, Y., Kuroda, T., Martuza, R., and Todo, T. (2005). Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Research 65, 10663–8.
11. Todo, T., Martuza, R. L., Rabkin, S. D., and Johnson, P. A. (2001). Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 98, 6396–401.
12. Chou, J., Kern, E. R., Whitley, R. J., and Roizman, B. (1990). Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 250, 1262–6.